0

l-DOPA and Its Receptor GPR143: Implications for Pathogenesis and Therapy in Parkinson's Disease

Yoshio Goshima, Daiki Masukawa, Yuka Kasahara, Tatsuo Hashimoto, Aderemi Caleb Aladeokin

Front Pharmacol. 2019 Oct 3;10:1119.

PMID: 31632270

Abstract:

l-3,4-Dihydroxyphenylalanine (l-DOPA) is the most effective therapeutic agent for Parkinson's disease (PD). l-DOPA is traditionally believed to be an inert amino acid that exerts actions and effectiveness in PD through its conversion to dopamine. In contrast to this generally accepted idea, l-DOPA is proposed to be a neurotransmitter. Recently, GPR143 (OA1), the gene product of ocular albinism 1 was identified as a receptor candidate for l-DOPA. GPR143 is widely expressed in the central and peripheral nervous system. GPR143 immunoreactivity was colocalized with phosphorylated α-synuclein in Lewy bodies in PD brains. GPR143 may contribute to the therapeutic effectiveness of l-DOPA and might be related to pathogenesis of PD.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP53587294 L-Dopa-(phenyl-d3) L-Dopa-(phenyl-d3) 53587-29-4 Price
qrcode

We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our Privacy Policy

Accept Cookies
x